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Non-motor symptoms are common in Parkinson’s disease (PD) and they represent a 
major source of disease burden. Several non-motor manifestations, such as rapid eye 
movement sleep behavior disorder, olfactory loss, gastrointestinal abnormalities, visual 
alterations, cognitive and mood disorders, are known to precede the onset of motor 
signs. Nonetheless, the mechanisms mediating these alterations are poorly understood 
and probably involve several neurotransmitter systems. The dysregulation of GABAergic 
system has received little attention in PD, although the spectrum of non-motor symptoms 
might be linked to this pathway. This Mini Review aims to provide up-to-date information 
about the involvement of the GABAergic system for explaining non-motor manifestations 
in early stages of PD. Therefore, special attention is paid to the clinical data derived from 
patients with isolated REM sleep behavior disorder or drug-naïve patients with PD, as they 
represent prodromal and early stages of the disease, respectively. This, in combination 
with animal studies, might help us to understand how the disturbance of the GABAergic 
system is related to non-motor manifestations of PD.
Keywords: GABA, REM sleep behavior disorder, hyposmia, visual alterations, gastrointestinal symptoms, 
neurotransmitters
INTRODUCTION
Parkinson’s disease (PD) is the second most common neurodegenerative disorder with a prevalence 
of between 1% and 4% in over-60-year-olds (Tysnes and Storstein, 2017). The diagnosis of PD 
currently depends on the identification of motor clinical features, including rest tremor, rigidity 
and bradykinesia. In addition, patients with PD develop a wide range of non-motor manifestations 
including cognitive impairment and dementia, mood and sleep disturbances, sensory abnormalities 
and autonomic nervous system dysfunction (Poewe, 2008). It has been estimated that the first motor 
signs appear when 50% to 80% of dopaminergic neurons in the substantia nigra pars compacta 
have been lost (Cheng et al., 2010). Thus, by the time of diagnosis, brain injury has been ongoing 
for years and any attempt at neuroprotection at this stage might be unsuccessful. Great efforts are 
being made to detect markers of neuronal dysfunction early in the course of the disease (Postuma 
and Berg, 2019). In relation to this, it is increasingly recognized that non-motor symptoms not only 
accompany but also precede motor signs in PD (Poewe, 2008). This is consistent with the Braak PD 
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staging system, which suggests that α-synuclein deposition starts 
in areas involved in sleep regulation, olfaction or autonomic 
function before affecting the basal ganglia or cerebral cortex 
(Braak et al., 2003). The array of premotor symptoms might 
help to identify patients at high risk of developing α-synuclein-
mediated neurodegenerative diseases, such as PD, dementia with 
Lewy bodies (DLB) or multiple system atrophy (MSA).
While the mechanisms for motor impairment are fairly well 
established, the neuroanatomical and molecular substrates for 
non-motor manifestations are far from clear. Current evidence 
suggests that neurotransmitters, such as acetylcholine, serotonin, 
noradrenaline, glutamate and gamma-aminobutyric acid 
(GABA), play an important role in the pathophysiology of PD 
(Sanjari Moghaddam et al., 2017). GABA is the main inhibitory 
neurotransmitter in the central nervous system (CNS), acts through 
GABAA and GABAB receptors, and is primarily released by local 
interneurons to regulate cortical and subcortical microcircuits 
(Figures 1A, B). GABAergic signaling modulates a wide range of 
physiological functions, including sensory perception, information 
processing and cognition. In patients with PD, GABAergic 
dysregulation has been observed in the basal ganglia postmortem 
and in vivo with magnetic resonance spectroscopy (Kish et al., 
FIGURE 1 | The GABAergic system and non-motor symptoms in Parkinson’s Disease. (A) GABA receptors. The inhibitory neurotransmitter GABA acts through 
ionotropic GABAA receptor or metabotropic GABAB receptor to reduce the membrane potential. The activation of GABAA receptors allows chloride (Cl-) entry into 
the cytoplasm, while GABAB receptor activation leads to a cellular cascade resulting in calcium (Ca2+) channel deactivation and potassium (K+) channel opening. 
(B) Schematic representation of cortical and subcortical local microcircuit organization of GABAergic cells. Inhibitory GABAergic cells are primarily local projecting 
neurons with a broad array of anatomical and physiological properties. The effect resulting from the inhibition exerted by GABAergic cells depends on their sensitivity 
to incoming stimuli, their firing properties and the subcellular domain of excitatory cells targeted by each interneuron. The diversity of GABAergic cells provides 
the brain with extensive computational power to regulate sensory and cognitive processes. (C) Brain areas associated with non-motor symptoms in Parkinson’s 
disease. Each color corresponds to a specific non-motor symptom and the associated area of the presumed GABAergic dysfunction.
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1986; Emir et al., 2012; O’Gorman Tuura et al., 2018). Recently, 
it has been shown that striatal dopaminergic axons co-release 
GABA (Tritsch et al., 2012; Tritsch et al., 2014), which suggests that 
dopaminergic neurodegeneration could lead to GABA decline in 
basal ganglia circuits (O’Gorman Tuura et al., 2018). Considering 
that GABAergic networks regulate calcium-mediated mechanisms, 
like mitochondrial function and oxidative stress, loss of GABA 
inhibitory tone would facilitate accumulation of abnormal levels 
of intracellular calcium, triggering neurodegenerative processes. 
Consistent with this idea, it has been shown that GABA agonists, 
such as Baclofen or Bumetadine, relieve motor symptoms and 
protect dopaminergic cell bodies in mice models of PD (Hajj et al., 
2015; Lozovaya et al., 2018). Nonetheless, GABAergic alterations 
might go beyond the basal ganglia. Unfortunately, few studies have 
investigated how GABAergic or other neurotransmitter systems 
may induce or modulate non-motor symptoms of PD. Identifying 
the separate role of each pathway may allow us to develop novel 
pharmacological compounds targeted to specific symptoms. 
Seeking to provide up-to-date information about the role of the 
GABAergic system, in this Mini Review, we focus on its ability to 
explain some of the non-motor manifestations that appear early in 
PD (Table 1).
REM SLEEP BEHAvIOR DISORDER 
AND PONTINE GABAERGIC CELL 
DYSFUNCTION IN PD
Sleep disturbances are the most common non-motor manifestations 
of PD, with wide variability in the reported prevalence (66% to 
98%) (Garcia-Borreguero et al., 2003). Sleep-related abnormalities 
in PD include insomnia, sleep fragmentation, restless legs 
syndrome, excessive daytime sleepiness and rapid eye movement 
(REM) sleep behavior disorder (RBD), among others. Some sleep 
abnormalities occur in early stages of the disease, even during the 
prodromal phase, including RBD (Iranzo et al., 2006), restless legs 
syndrome (Wong et al., 2014) and excessive daytime sleepiness 
(Abbott et al., 2005). Nonetheless, only idiopathic RBD (iRBD) has 
consistently shown to be an early predictor of the development of 
PD (Iranzo et al., 2017) (Postuma and Berg, 2019).
RBD is a parasomnia characterized by the loss of the normal 
muscle atonia of REM sleep. The diagnostic hallmark is excessive 
electromyographic activity during REM sleep as documented 
by polysomnography (Ferini-Strambi et al., 2016). Patients 
with RBD report the enactments of dreams, including kicking, 
punching or talking. In the absence of other neurological signs 
or CNS lesions, patients with iRBD are at high risk of developing 
α-synuclein-mediated neurodegenerative diseases in the years 
following the diagnosis (Hogl et al., 2018). It has also been 
suggested that the presence of RBD in PD patients is associated 
with an aggressive phenotype, these patients showing a higher 
density of α-synuclein aggregates (Knudsen et al., 2018).
Therefore, in recent years, special attention has been paid to 
PD-related non-motor manifestations and symptom progression 
in iRBD patients, seeking to find novel biomarkers of PD. Although 
the precise pathophysiological mechanisms for iRBD have not been 
fully determined, iRBD seems to be attributable to neurochemical 
imbalances in sleep regulatory systems (Boucetta et al., 2014). 
Previous studies have pointed toward a significant and specific 
neurodegeneration of GABA or glycine-containing neurons in the 
ventral medulla, such as in the nucleus raphe magnus and the ventral 
gigantocellular, alpha gigantocellular and lateral paragigantocellular 
reticular nuclei that directly project to spinal motor neurons to 
produce atonia during REM sleep (Iranzo, 2018) (Figure 1C). This 
hypothesis is supported by preclinical studies in transgenic mice 
that exhibit an RBD phenotype when glycine and GABA receptor 
function is impaired (Brooks and Peever, 2011). Moreover, allosteric 
agonists that bind at the α/γ subunit interface of GABAA receptors, i.e., 
benzodiazepines, including clonazepam, triazolam or alprazolam, are 
the first-line therapy in iRBD (Anderson and Shneerson, 2009), and 
the effectiveness of this treatment could be explained by GABAergic 
neurotransmission disruption in prodromal stages of PD.
OLFACTORY LOSS AND ITS 
RELATIONSHIP wITH GABAERGIC 
NEUROTRANSMISSION IN PD
Olfactory dysfunction is observed in more than 90% of PD 
patients (Doty, 2012), frequently precedes the onset of motor 
TABLE 1 | Evidence of the involvement of GABAergic neurotransmission in early 
non-motor symptoms of Parkinson’s disease.
Non-motor 
symptom
Evidence of GABAergic inhibitory deficit
REM sleep behavior 
disorder
GABAergic cells in the ventral medulla are 
dysfunctional † (Brooks and Peever, 2011)
Olfactory loss Tonic inhibition exerted by interneurons regulates odor 
detection (Pirez and Wachowiak, 2008; Shao et al., 
2009; Acebes et al., 2011)
Visual perception 
alterations
GABAergic depletion in the retina changes contrast 
sensitivity † (Hilgen et al., 2015)
GABA antagonism in visual cortex decreases stimulus 
orientation and direction selectivity † (Katzner et al., 
2011)
GABA levels in visual cortex are predictive of 
visuospatial abilities * (Cook et al., 2016)
Visual hallucinations are associated with decreased 
occipital GABA in PD (Firbank et al., 2018) and with 
the loss of postsynaptic GABA markers in DLB ** 
(Khundakar et al., 2016)
Cognitive impairment GABA transcriptional changes in the frontal cortex ** 
(Santpere et al., 2018)
Levels of PV and GAD67 mRNA expression are low 
in the frontal cortex ** (Lanoue et al., 2013; Lanoue 
et al., 2010)
Anxiety and 
depression
GABAA receptor positive modulators are anxiolytic 
and antidepressant, while negative modulators 
produce anxiogenic and depressive-like effects †,* 
(Kalueff and Nutt, 2007; Mohler, 2012)
GABA receptor dysfunction is linked to anxiety and 
depression-like behaviors † (Kalueff and Nutt, 2007)
Gastrointestinal 
symptoms
GABA regulates the mobility and inflammatory 
responses of the gastrointestinal tract # (Auteri et al., 
2005a; Auteri et al 2005b; Jin et al., 2013)
†Studies conducted in animal models, #physiological function, * in healthy 
controls, ** in patients with Parkinson’s disease (PD) or dementia with Lewy 
bodies (DLB).
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symptoms (Fantini et al., 2006; Ross et al., 2008; Postuma 
et  al., 2009), and predicts the early conversion of iRBD to PD 
or DLB (Mahlknecht et al., 2015; Fereshtehnejad et al., 2017). 
The mechanisms responsible for olfactory dysfunction in PD are 
currently unknown. Magnetic resonance imaging studies have 
shown significantly smaller olfactory bulb volumes in patients 
with PD than controls (Brodoehl et al., 2012; Li et al., 2016; Tanik 
et al., 2016), although other authors failed to find such differences 
(Altinayar et al., 2014). Axonal and myelin damage of olfactory 
tracts has also been observed using diffusor-tensor imaging 
(Scherfler et al., 2006; Scherfler et al., 2013). These results have 
been confirmed by postmortem analysis of olfactory bulbs, in 
which global glomerular voxel volume was found to be smaller 
in five PD cases than six healthy controls (Zapiec et al., 2017). 
Moreover, hyposmia has been related to pathological changes in 
other areas of the olfactory system, such as the anterior olfactory 
nucleus or basolateral nucleus of the amygdala (Pearce et al., 1995; 
Harding et al., 2002). On the other hand, sensory perception 
disturbances might represent subtle alterations of normal 
functioning that precede neuronal degeneration. Changes in 
network connectivity of brain structures related to olfaction have 
already been described (Westermann et al., 2008; Bohnen et al., 
2010; Wen et al., 2017), and these functional abnormalities may 
arise from iron and sodium deposition (Gardner et al., 2017).
The limited literature about the precise anatomy and 
physiology of the human olfactory bulb makes it difficult to assess 
the mechanisms related to olfactory dysfunction in humans. 
In this regard, animal studies provide a wealth of knowledge, 
as the olfactory bulb of rodents has been well characterized. It 
has been shown that interneurons—GABA-releasing cells—are 
essential for odor detection, and functionally distinct GABAergic 
circuits within the olfactory bulb of rodents play different roles 
in olfactory coding. The tonic inhibition exerted by these cells 
is thought to regulate the sensitivity of odor detection and odor 
perception in the mammalian brain (Pirez and Wachowiak, 
2008; Shao et al., 2009; Acebes et al., 2011) (Figure 1C). Even 
though animal findings suggest that interneuron connectivity 
is the major determinant of odor perception, whether the loss 
of inhibitory synapses contributes to olfactory changes in PD in 
humans needs further research.
vISUAL DISTURBANCES
Among primary visual functions, low-contrast visual acuity, 
contrast sensitivity and color vision are typically affected in PD 
(Weil et al., 2016). Patients with drug-naïve PD or iRBD also 
show decreased contrast sensitivity (Righi et al., 2007; Marques 
et al., 2010), and abnormal color vision discrimination has 
been described in iRBD, these patients having a 3-fold higher 
risk of conversion (Postuma et al., 2015). Nevertheless, color 
discrimination is not consistently impaired in the early stages 
of PD, indicating that color vision abnormalities may represent 
a specific PD phenotype (Vesela et al., 2001). Indeed, Postuma 
and colleagues reported that abnormal color vision in iRBD was 
a stronger predictor of primary dementia than parkinsonism 
(Postuma et al., 2015), which is in line with findings in PD, RBD 
increasing the risk of cognitive decline (Pagano et al., 2018). 
Patients with iRBD or de novo PD also display visuoconstructional 
and visuoperceptual disturbances that may be related to non-
dopaminergic impairment (Ferini-Strambi et al., 2004; Gagnon 
et al., 2009; Aarsland et al., 2009a; Marques et al., 2010; Fantini 
et al., 2011; Kim et al., 2011; Ota et al., 2016).
In vivo neuroimaging studies in newly diagnosed and drug-
naïve PD patients have detected structural alterations in the 
visual pathway, ranging from thinning of inner retinal layers 
to increased optic radiation mean diffusivity and reduced 
visual cortical volumes (Arrigo et al., 2017; Ahn et al., 2018; 
Murueta-Goyena et al., 2019), which might explain some visual 
disturbances. There is, however, a growing body of evidence 
highlighting the role of GABA in perceptual aspects of vision.
Retinal amacrine cells co-release dopamine and GABA and 
the degeneration of these specialized cells has been suggested 
to cause primary visual dysfunction, although this hypothesis 
has not been confirmed (Nguyen-Legros, 1988). In line with 
this, pharmacological depletion of endogenous retinal GABA 
with allylglycine induces changes in contrast sensitivity (Hilgen 
et al., 2015). On the other hand, animal studies have shown that 
GABAA receptor antagonist infusion in cat primary visual cortex 
decreases selectivity for stimulus orientation and direction, but 
not contrast sensitivity (Katzner et al., 2011). More recently, it 
has been observed that GABA levels measured by magnetic 
resonance spectroscopy are strong predictors of visuospatial 
abilities in healthy adults (Cook et al., 2016), and increasing 
GABA activity with systemic midazolam injections decreases 
visual sensitivity, preferentially affecting medium-to-high spatial 
frequencies and low temporal frequencies (Blin et al., 1993). 
Additionally, higher GABA concentrations in the visual cortex, 
as well as administration of the GABA agonist lorazepam, induce 
slower perceptual dynamics (van Loon et al., 2013).
These findings suggest that GABA signaling plays a central role 
in visual perception and a disturbance of this circuit at any level 
of the visual pathway could influence proper sensory processing. 
Consistent with this, recent studies show that PD patients with 
visual hallucinations have low occipital GABA concentrations 
(Firbank et al., 2018), and complex visual hallucinations in 
DLB are associated with altered GABAergic synaptic activity 
(Khundakar et al., 2016), which further supports the view that 
dysregulation of GABAergic system is involved in the visual 
pathway of PD (Figure 1C). Whether this system is affected in 
the retina and visual cortex of all PD patients, and from early 
stages, remains to be determined.
COGNITIvE DYSFUNCTION AND 
GABAERGIC SIGNALING IN 
FRONTOSTRIATAL CIRCUITS
Cognitive manifestations are frequently reported in PD, with a 
prevalence of 20–25% for mild cognitive impairment and 30% 
for dementia. It is estimated that PD patients have a 3- to 6-fold 
higher risk of developing dementia than age-matched controls 
(Svenningsson et al., 2012). Cognitive dysfunction is thought to 
be one of the key premotor manifestations of PD. At diagnosis, 
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15–20% of PD patients have mild cognitive impairment 
(Aarsland et al., 2009b) and several studies in patients with iRBD 
have identified cognitive disturbances, including delayed verbal 
memory, poorer decision-making, worse attention and slower 
processing speed, these domains being predictive of future risk of 
developing PD or DLB (Fantini et al., 2011; Terzaghi et al., 2013; 
Youn et al., 2016; Genier Marchand et al., 2017). Thus, early onset 
cognitive abnormalities are mainly dependent on the frontal lobe 
(Ferini-Strambi et al., 2004; Massicotte-Marquez et al., 2008; 
Sasai et al., 2012; Chahine et al., 2018).
Despite the evidence of neuropathological abnormalities in 
frontal brain areas in PD, their molecular and cellular alterations 
are poorly understood. Several studies have suggested that 
cognitive impairment in PD is attributable to neurotransmitter 
dysregulation rather than frank neurodegeneration (Kehagia 
et al., 2010; Ray and Strafella, 2012). Dopamine and acetylcholine 
deficiencies in frontostriatal pathways play a major role in 
cognitive impairment in PD, but the contribution of the other 
neurotransmitter systems remains less certain. Regarding the 
role of GABA, in frontal cortex global transcriptional changes 
of GABAergic neurotransmission have been observed in DLB 
patients (Santpere et al., 2018). It has also been shown that 
mRNA expression of the GABA-synthesizing enzyme glutamic 
acid decarboxylase-67 (GAD67) (Lanoue et al., 2010) and the 
calcium-binding protein parvalbumin (PV) (Lanoue et al., 
2013)—two key markers of GABAergic cells—is low in the 
dorsolateral prefrontal cortex of PD patients without evidence 
of cell loss, further suggesting the downregulation of inhibitory 
neurotransmission in the frontal cortex (Figure 1C). In basal 
ganglia, in vivo GABA concentration changes have been detected 
in PD patients performing cognitive tasks (Buchanan et al., 
2015). Interestingly, boosting GABAergic neurotransmission by 
zolpidem administration in early stage PD patients modulates 
aberrant beta-frequency oscillations (Hall et al., 2014), and the 
desynchronization of low-frequency activity seems to restore 
cognitive functions (Hall et al., 2010). Although these findings 
point towards decreased GABAergic activity in frontostriatal 
circuits in PD and DLB, whether GABAergic neurotransmission 
is also perturbed in premotor stages of PD has not been 
established, and its contribution to cognitive dysfunction needs 
to be elucidated in future studies.
GABA IN ANXIETY AND DEPRESSION
Anxiety and depression are common non-motor symptoms 
of PD, with reported prevalence rates of 20–40% (Chen and 
Marsh, 2014) and 50% (Reijnders et al., 2008), respectively, and 
may precede motor signs (Jacob et al., 2010). Notably, RBD 
patients score worse on anxiety and depression scales than 
controls and even PD patients (Barber et al., 2017). Although 
the exact neurobiological mechanisms that underlie anxiety 
and depression have not been fully elucidated, they seem to be 
intrinsically interrelated.
Pharmacological studies in both humans and animals have 
revealed that positive modulators of GABAA receptors are anxiolytic 
and antidepressant, whereas negative modulators produce 
anxiogenic and depressive-like effects (Kalueff and Nutt, 2007; 
Mohler, 2012). Agents that enhance GABAA receptor conductance 
(e.g., benzodiazepines) and GABA metabolism (e.g., valproate, 
vigabatrin, and tiagabine) exert anxiolytic effects, and it seems 
that partial agonists of α2/α3 GABAA receptors, such as TPA-023, 
may also serve as antidepressants (Mohler, 2012). Furthermore, 
genetic studies implicate GABA-receptor dysfunction in the risk 
of developing anxiety and depression (Kalueff and Nutt, 2007). 
Recent evidence suggest that somatostatin contributes to the 
pathology of anxiety and depression (Fuchs et al., 2016; Fee et al., 
2017), levels of this GABAergic marker being low in cerebrospinal 
fluid and induced pluripotent cells of PD patients (Dupont et al., 
1982; Iwasawa et  al., 2019). Nonetheless, there is still a lack of 
studies exploring the role of somatostatin in anxiety and depressive 
disorders in PD.
GASTROINTESTINAL SYMPTOMS AND 
GABA SIGNALING IN THE ENTERIC 
NERvOUS SYSTEM
Gastrointestinal disturbances fall within the spectrum of 
autonomic manifestations of PD patients. Hypersalivation, 
dysphagia, nausea, gastroparesis, small intestinal dysfunction, 
slow transit constipation and defecatory dysfunction have been 
attributed to α-synuclein-mediated small fiber neuropathy of the 
enteric nervous system (ENS) and to the neurodegeneration of 
the enteric branches of the vagus nerve in the brainstem (Pfeiffer, 
2018). Among the gastrointestinal symptoms, constipation is the 
most frequent manifestation in PD and recent evidence suggests 
that it might also be one of the most common disturbances in 
prodromal PD (Stirpe et al., 2016). A multicenter study of 318 
patients with polysomnography-confirmed iRBD concluded that 
they had substantially more autonomic symptoms than controls 
(SCOPA-AUT questionnaire), gastrointestinal symptoms 
being the most prominent domain (Ferini-Strambi et al., 
2014). Nonetheless, gastric emptying measured with the 13C‐
octanoate breath test showed that only drug‐naïve and early‐
stage Parkinson’s disease patients had delayed gastric emptying, 
authors suggesting that changes in structures modulating gastric 
motility might not be sufficiently severe in iRBD (Unger et al., 
2011).
The last three decades have seen an expansion in the literature 
on the role of GABA in the control of gastrointestinal function, 
including mobility and inflammatory responses (Auteri et al., 
2015a; Auteri et al., 2015b). GABA has been identified as an 
important modulator of gastrointestinal tract function. This 
neurotransmitter can stimulate or inhibit the enteric neurons 
acting though GABAA or GABAB receptors (Auteri et al., 
2015a). Its role is particularly important in the colon, where 
it modulates the peristatic reflex. On the other hand, enteric 
inflammation occurs in PD and has been related to the initiation 
and progression of the disease (Houser and Tansey, 2017). 
Nonetheless, it has yet to be determined why the production 
of pro-inflammatory cytokines takes place in the enteric tract. 
The purinergic system controls enteric inflammation, but GABA 
also has a major role in immune cell activity and inflammatory 
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events in the gastrointestinal tract (Jin et al., 2013). Topiramate—
an anti-epileptic drug that acts as a GABAA agonist—reduces 
gastrointestinal inflammation in rats (Dudley et al., 2011), 
identifying GABA as a putative neuroimmune modulator. A 
better understanding of the relationship of GABA signaling with 
intestinal motility and inflammation is necessary, however, to 
reveal a possible functional link between this neurotransmitter, 
the ENS, and gastrointestinal symptoms of PD.
FINAL REMARKS AND CONCLUSIONS
Current evidence supports the view that PD is a degenerative 
disorder that affects multiple systems and presents with several 
non-motor symptoms. Over recent years, the importance of 
early, non-motor manifestations of PD has been increasingly 
recognized, as they may help to identify patients at high risk 
of developing α-synucleinopathies. Even though the neuronal 
circuits for motor symptoms are fairly well understood, the 
pathophysiological mechanisms for perceptual, cognitive, mood 
and autonomic disturbances of PD remain unclear.
Here, we report evidence consistent with the view that the 
GABAergic system is altered in PD and may contribute to 
non-motor symptoms that appear early in disease progression. 
Nonetheless, the literature in this field is dominated by non-
placebo controlled and postmortem studies, generally based on 
small series and providing low-level evidence. To summarize, 
based on current findings, PD patients in premotor stages 
have anxiety and depression and alterations in the olfactory 
system, visual perception and visuospatial abilities, 
frontostriatal-related cognition, and gastrointestinal function. 
The neurobiological correlates of these deficits are unclear, in 
part because of the complex dynamic interactions between 
several neurotransmitter systems. Still, the dysfunction of 
GABAergic neurons in ventral medullary reticular formation 
seems to be linked to RBD. Moreover, preclinical studies 
show the relevance of interneurons in odor detection and 
the causal role of GABA in anxiety and depressive disorders, 
but we are far from establishing whether this also occurs in 
PD. On the other hand, disturbance of GABA signaling by 
pharmacological compounds affects visual processing and 
cognition, and GABA levels in the visual cortex are low in 
PD patients with visual hallucinations. It has been also shown 
that GABA controls gastrointestinal function, although it is 
not known whether this is associated with the gastrointestinal 
symptoms reported by PD patients. All these findings suggest 
that intervening in GABAergic signaling might modulate non-
motor manifestations of PD and provide a novel avenue for 
non-dopaminergic therapy.
Nevertheless, there is a paucity of replication and large 
case-control studies. Future research should include in vivo 
longitudinal studies that examine the link between alterations 
in the GABAergic system and early non-motor symptoms 
by exploiting advances in PET ligands, magnetic resonance 
spectroscopy and CSF biomarkers. Preclinical studies might 
help to investigate the effects of GABA in the pathogenesis 
of non-motor symptoms, but we suggest that identifying the 
neurotransmitter deficits that correlate with clinical severity 
should be the mainstay for guiding future treatment studies.
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